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Abstract
Background: Function exertion of specific proteins are key factors in disease progression, thus the systematical
identification of those specific proteins is a prerequisite to understand various diseases. Though many proteins
have been verified to impact on hepatitis, no systematical protein screening has been documented to hepatitis B
virus (HBV) induced hepatitis, hindering the comprehensive understanding to this severe disease.
Aim: To identify the major proteins in the progression of HBV infection from mild stage to severe stage.
Methods: We performed an integrated strategy by combining two-dimensional electrophoresis (2-DE), peptide
mass fingerprinting (PMF) analysis, and tissue microarray techniques to screen the functional proteins and detect
the localization of those proteins.
Results: Interestingly, MS/MS identification revealed the expression level of alpha-1 antitrypsin (AAT) was
significantly elevated in serum samples from patients with severe chronic hepatitis. Immunoblotting with a specific
AAT antibody confirmed that AAT is highly expressed in serum samples from patients with hepatic carcinoma and
severe chronic hepatitis. Furthermore, we observed that AAT is with highest expression in normal tissue and cells,
but lowest in hepatic carcinoma and severe chronic hepatitis tissues and cells, suggesting the specific secretion of
AAT from tissues and cells to serum.
Conclusion: These results suggest the possibility of AAT as a potential biomarker for hepatitis B in diagnosis.
Introduction
Alpha-1 antitrypsin (AAT) is the most prominent pro-
tease inhibitor in human serum. More than 70 genetic
variants of AAT have been described. It was documen-
ted that ATT deficiency associates with various types of
liver diseases, such as neonatal hepatitis [1], cirrhosis
and hepatoma [2].
Hepatitis B continues to be a worldwide clinical pro-
blem with approximately 300 million people chronically
infected. Chronic infection is associated with significant
morbidity and mortality as a result of long-term seque-
lae including inflammatory liver disease, cirrhosis, and
hepatocellular carcinoma [3]. It’s well known that differ-
ent functions of specific proteins play crucial roles in
hepatitis B virus (HBV) induced hepatitis, thus compre-
hensive identification of those specific proteins may
greatly advance the disease diagnosis and biomarker
search. To this end, many technologies were developed
to identify disease associated proteins and biomarkers
in diagnosis. Among them, proteomic analysis is a
powerful tool to advance the diagnosis, treatment, and
prevention of human diseases [4,5]. Two-dimensional
electrophoresis (2-DE) is also widely used to identify
biomarkers for diagnosis and therapeutic strategies.
Steel et al. [6] constituted a proteomic approach for the
discovery of early detection markers of hepatocellular
carcinoma and Qing-Yu He et al. [7] used SELDI-Pro-
teinChip combined with 2-DE to identify biomarkers in
the serum samples of hepatitis B and hepatic carcinoma.
However, these technology-dependent studies only dis-
played the expression of protein in the serum, but pro-
tein origin information was not provided, hindering the
deep understanding to the investigated diseases.
In this study, we first applied 2-DE to screen specific
proteins in the serum samples from mild and severe
hepatitis B patients and alpha-1 antitrypsin (AAT) with
high expression was identified. Using tissue microarray
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technique with few reagents [8], we confirmed the AAT
identification by 2-DE. Furthermore, SELDI-TOF MC
PMF was used to expand the protein information. Our
studies thus provided useful information of the origin
of AAT, which will be valuable for further explorations,
especially specific amino acids.
Materials and methods
Patient Materials
Approved by the local ethics committee, 31 chronic
hepatitis B patients (13 mild and 18 severe), 10 conva-
lescent acute hepatitis B (AHB), 18 HBV-related Hepa-
tocellular Carcinoma (HCC) patients and 12 healthy
blood donors (normal controls) were enrolled in this
study. The standards for diagnoses have been described
previously [9]. All patients were HBsAg positive, and
patients with hepatitis C, hepatitis D, human immuno-
deficiency virus type 1[HIV-1] positive and HIV-2 nega-
tive as well as with other chronic liver damages were
excluded. Venous blood was collected and centrifuged
at 2000 μg for 10 min. The supernatant were obtained
and stored at -80°C.
2-DE protein separation
In order to identify the target proteins in the progress of
HBV patients from mild to severe, one-milliliter of
serum was collected from each patient of these two
groups. The serum from mild and severe group were
separately mixed. The serum albumin and IgG were
removed using an albumin and IgG removal kit (GE
healthcare, London, UK). The protein concentrations
were determined by a Bradford assay. 2-DE was per-
formed with IPGphor IEF (Amersham Biosciences,
Uppsala, Sweden) and Ettan Dalt six electrophoresis
units with the protocol suggested by the manufacturer.
Isoelectric focusing (IEF) was performed using 240 mm
IPG strips with IPGphor system. Two hundred micro-
grams of protein sample was diluted with rehydration
solution (8 M urea, 2% (w/v) CHAPS, 0.5% (v/v) IPG
buffer pH 4-7, 0.002% (w/v) bromophenol blue) to 450
μl and then loaded on the strip holder. Six gels were
separated at once, three per group. The IPG gels were
rehydrated for 12 hrs under 30 V at 20 W. IEF was per-
formed with the following parameters: 500 V for 1 h,
1000 V for 1 hr, 8000 V for 8 hrs and 20 min. After
IEF, the strips were equilibrated for 15 min in SDS equi-
libration buffer (6M urea, 2% (w/v) SDS, 50 mM Tris-
HCl pH 8.8, 30% (v/v) glycerol, 0.002%(w/v) bromophe-
nol blue) containing 100 mM DTT and then in SDS
equilibration buffer containing 250 mM idoacetamide.
After equilibration, the strips were loaded onto a vertical
12.5% (w/v) SDS-PAGE gels and sealed with 0.5% (w/v)
agarose. The vertical electrophoresis was performed at
10 W with a condition of 5 W/gel for 30 min followed
by 15 W/gel until the bromophenol blue dye reached
the bottom of the gel.
Silver staining and imaging of 2DE gels
The gels were fixed with 40% (v/v) ethanol and 10%
(v/v) acetic acid over night, and then incubated in the
sensitizing solution (30%(v/v) ethanol, 0.2%(w/v) sodium
thiosulphate and 6.8% (w/v) sodium acetate) for 30 min.
After washing three times with milli-Q water for 15 min
each, the gels were stained with 0.25% (w/v) silver
nitrate solution for 20 min. Development was performed
in 2.5% (w/v) sodium carbonate with 0.04% (v/v) formal-
dehyde for 5 min. Stop solution (1.46%(w/v) EDTA) was
used to terminate the reaction.
In-gel trypsin digestion of proteins
The selected protein spots from all gels were excised and
placed in Eppendorf tubes and digested as previously
described [10]. After washing twice in milli-Q water, the
gels were destained with a 1:1 mixture of 30 mM potas-
sium ferricyanide and 100 mM sodium thiosulfate. The
gels were then washed twice in milli-Q water, dehydrated
with ACN and dried in a SpeedVac for 20 min. The gels
were digested over night with 10 μl of 20 ng/μl sequen-
cing grade trypsin at 37°C. The peptide fragments were
extracted with 30 μl solution containing 50% (v/v) ACN
and 5% (v/v) TFA. The solutions containing peptide frag-
ments were dried in a lyophilizer and reconstituted by
adding 10 μl of 0.1% (v/v) formic acid.
MALDI-TOF-MS analysis of tryptic peptide
MS/MS analysis was performed using a Bruker-Dal-
tonics AutoFlex TOF-TOF LIFT Mass Spectrometer
(Bruker, Germany) operated in the delayed extraction
and linear mode. The tryptic digest mixture was mixed
with HCCA matrix. The MALDI spectra averaged over
50 laser shots. All mass spectra were calibrated exter-
nally by using a standard peptide mixture (HCCA).
Internal calibration was performed using automatic
digestion peaks of trypsin.
Database searching and identification of proteins
Peptide mass fingerprints obtained by the MALDI-TOF
MS were used to search NCBInr using Mascot software.
The parameters used for the search were as follows: (1)
peptide mass ranged from 1,000 to 3,000 U; (2) modifi-
cations were allowed for carbamidomethyl and oxida-
tion; (3) one missed cleavage site was allowed; (4) mass
accuracy was ± 1U, and (5) restriction was placed on
the species of Mus. The criteria for positive identifica-
tion of proteins were set as follows: (1) the MS match
consisted of a minimum of four peptides; (2) the
matched peptides covered at least 20% of the whole pro-
tein sequence, and (3) 100 ppm or better mass accuracy.
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Preparation of AAT polyclonal antibody
An anti-human AAT rabbit polyclonal antibody was
generated by EPITOMICS (EPITOMICS, USA), recog-
nizing the amino acid residues 301 to 314. The antibody
generation procedure was described as previously [11].
Western Blotting
Serum proteins (10 ug) from each patient of mild, severe
CHB patients, acute hepatitis B patients, HCC patients,
and healthy control groups were separated on 12% SDS-
PAGE gels, and then transferred onto PVDF mem-
branes. After incubating with blocking solution (TBS-T
containing 5% non-fat milk) under room temperature
for 2 hrs, the membranes were probed with anti-human
AAT rabbit polyclonal antibody at 4°C overnight. After
washing four times of 10 min each with TBS-T, anti-
rabbit (horse-radish peroxidase) HRP secondary anti-
body was added for 1 hr at room temperature, and the
antigen-antibody interaction was detected by ECL detec-
tion kit and exposed to X-ray film.
Immunohistochemical analysis of tissue microarrays
A tissue microarray block with 24 tissue sample cores
(each 1.5 mm in diameter) was purchased from Cybrdi
(CC03-11-002, United States). The 24 tissue samples
were formalin-fixed, paraffin-embedded liver samples
consisting of six cases of multiple types of cancer with
matched normal controls. Slides from the tissue micro-
array block were deparaffinized. For antigen retrieval,
the sections were immersed in citrate buffer and pro-
cessed in a scientific microwave oven at 95°C for 10
min. After pretreatment with biotin blocking, rabbit
anti-human AAT rabbit polyclonal antibody was applied
at a dilution of 1:1000 and incubated at 4°C overnight.
Biotinylated goat anti-rabbit IgG (1:100 dilution; Dako,
Gene Tech) was used as a secondary antibody. Negative
controls were created by omitting the primary antibody.
Assessment of AAT was based on the percentage of
positive stained cells on a 3-point scale (0, absence of
staining; 1+, moderate staining; 2+, strong staining).
Cell line culture, extraction, and western blotting
Chang cells, HepG2, Huh7, 7402, 7721 cells were cul-
tured in DMEM medium supplemented with 10% (v/v)
fetal bovine serum (FBS) and antibiotics. The cells were
maintained in an incubator at 37°C with CO2 in humidi-
fied atmosphere. The cells at the exponential growth
phase were harvested with trypsinization. Then cells were
lysed with lysis buffer (30 mM Tris, pH7 .5, 150 mM
sodium chloride, 1 mM phenylmethylsulfonyl fluoride, 1
mM sodium orthovanadate, 1% Nonidet P-40, 10% gly-
cerol) [12] for 15 mins at 4°C, vortexed and centrifuged
at 13000 rpm at 4°C for 30 min. The supernatants were
mixed in Laemmli loading buffer, boiled for 10 min, and
then subjected to SDS-PAGE gels.
Results
The screening of specific proteins associated with severe
hepatitis B
To screen the proteins contributing to the progress of
chronic hepatitis B (CHB), 2DE separation of serum
protein was performed. 2-DE separation was performed
three times for each sample of one group to minimize
gel-to-gel variation (Figure 1A/B). Figure 1A showed the
representative gel images from patients with mild CHB,
while Figure 1B showed the image from patients with
severe CHB. Spot size was compared between two gel
images with ImageMaster. With the same quantity of
total serum protein loading, it was clearly observed that
the size of most spots in Figure 1B is smaller than those
in Figure 1A except one area indicated in Figure 1C.
Due to the unexpected observation, we next focused on
those proteins in the following studies.
Protein identification
The spot highlighted in Figure 1C was excised and sub-
jected to trypsin digestion followed by MALDI-TOF
identification. Database searching suggested it was
alpha-1 antitrypsin (AAT) (Table 1, Figure 2).
Western blot analysis of serum protein
To further confirm the protein identified by MALDI-
TOF, western blotting was performed with the generated
ATT antibody. In order to reveal the relationship
between hepatitis B and AAT, more samples from differ-
ent patients including healthy controls, acute hepatitis,
and chronic hepatitis (including mild, severe, and hepatic
carcinoma) were included. Among the serum samples
from those groups, six samples in each group were ran-
domly selected and subjected to the immunoblotting with
anti-human AAT rabbit polyclonal antibody. With equal
loading amount, highest ATT expression levels were in
carcinama and severe chronic hepatitis B samples, but
relatively lower in serum samples from normal and mild
CHB patients (Figure 3), which is consitent with the
results of 2-DE gel seperation.
AAT immunostaining on tissue microarrays
Immunostaining for AAT was performed on the consecu-
tive tissue microarray sliders. A total of 24 samples were
analyzed, and 13 of those were divided into four types as
cholangiocarcinoma, hepatocellular carcinoma, transpar-
ent hepatocellular carcinoma, and moderate differentiated
metastatic adenocarcinoma. Eleven of those samples were
noncancerous liver samples including chronic hepatitis
and normal liver samples. Non-cancerous livers with
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chronic hepatitis and normal liver samples exhibit signifi-
cant cytoplasmic staining of AAT compared with the
HCC’s (Figure 4). Even in the one slide of HCCs, the
noncancerous area was found to be significantly
expressed with AAT compared with the carcinoma areas.
Western blotting analysis of protein from cell lines
To further confirm the results from tissue microarrays,
we next carried out western blotting in different cell
lines including hepatic carcinoma cell line HepG2, 2215,
HepG2, Huh7, BEL-7402 [13], SMMC-7721 [14] and
normal hepatic cell line Chang [15]. With equal protein
loading, proteins from all cell lines were subjected to
the immunoblotting with anti-human AAT rabbit poly-
clonal antibody. As shown in Figure 5, the AAT signal
was only detected in normal hepatic Chang cells, but
not in other cell lines. These results are consistent with
the data from tissue microarrays.
Discussion
Identification of biomarkers with proteomic technology
has become an important tool in biomedical research.
The development of proteomics, especially two-dimen-
sional electrophoresis associated with MS/MS, provides
tremendous assistance to screen the biomarkers in var-
ious diseases. Many studies focus on biomarker identifica-
tion for HBV infection [16,17], liver fibrosis, or cirrhosis
that may result in HCC [18]. However, the methodology
used in these studies only detect proteins in the serum,
but not the tissues that secret or express these proteins.
J. Kenonen et al. [19] firstly introduced microarray
technology in biomedical research, making hundreds of
samples to be detected simultaneously by either immu-
nohistochemistry or in situ hybridization on a single tis-
sue slice [20,21]. As a result, in our study we combined
2-DE with high-throughput tissue microarray technology
to study proteins that may be involved in the progres-
sion of mild hepatitis B infection to severe or even HCC
in the patients. According to the result of SELDI-TOF
MS PMS, we identified the highly expressed AAT in
serum samples from patients with hepatic carcinoma
severe hepatitis B.
To study the association between AAT and hepatitis B
and HBV-related HCC, we prepared polyclonal antibody
Figure 1 2-DE images of serum proteins from patients with mild (A) and severe (B) chronic hepatitis. The significantly higher expressed
protein with 44kD (C) was further analysed by PMF.
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against AAT and performed western blotting exam.
Results showed the gradual increase of serum AAT level
from normal to hepatitis B patients and then to the
HCC group. We further performed immunohistochem-
ical analysis on hepatic tissue microarray slice. To verify
the result of tissue chips, we further examined the AAT
expression in different cell lines including HepG2 Huh7
7402 and 7721 hepatoma cell lines (Chang cells were set
as normal control) by western blotting and the results
showed AAT was only expressed in Chang cells but not
other hepatitis cells or hepatic hepatoma cells. The dis-
crepancy of ATT expression in serum and tissue/cell
samples suggested the different mechanism by which
ATT is expressed/secreted.
Blood plasma is with exceptional proteome in many
respects, containing other tissue proteomes as subsets.
As a widely used research subject, serum has its intrinsic
advantages such as the convenience for preparation and
rich aspects linking with various diseases. However,
Figure 3 The high expression of ATT in severe hepatitis B
patients (Ca: hepatic carcinoma; S: severe hepatitis B; M: mild
hepatitis B; A: acute hepatitis; N: normal).
Figure 2 MALDI-TOF MS spectrum of alpha-1 antitrypsin. The major peaks are well matches to the protein sequence with probability based
mowse score is 67. [Protein score is -10*Log(P), where P is the probability that the observed match is a random event. Protein scores greater
than 65 are significant (p < 0.05).].
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there are many disadvantages such as proteins in serum
from various tissue proteomes, which makes serum not
able to be used to determine the origins of disease asso-
ciated proteins [22]. In our experiments, though the
conclusion of AAT levels in serum, tissue and cell lines
were not consistent, it is not difficult to understand that
the high ATT level in serum may be secreted from
hepatic carcinoma or hepatitis cells by certain inflamma-
tory molecules or signal pathway activation, causing
ATT levels in hepatic carcinoma or hepatitis cells invisi-
ble. On the other hand, the high level of AAT in serum
may be derived from normal liver cells and represent
self-protective responses of the liver cells as observed in
other studies [23].
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